The open letter, signed by 150 organizations, to the Senate HELP committee on medical innovations legislation (The Cancer Letter, April 29, 2016).
Fitzpatrick Letters: FDA's letter on inspections of hospitals on adverse outcomes reporting, and Rep. Mike Fitzpatrick's (R-Pa.) letter to Vice President Joe Biden on medical device safety regulations, the Cancer Moonshot and the FDA Oncology Center of Excellence (The Cancer Letter, April 15, 2016).
The FDA's order granting PneumoLiner Class II device classification (The Cancer Letter, April 8, 2016).
Amy Reed's consent form for her power morcellation procedure at Brigham and Women's Hospital (The Cancer Letter, April 8, 2016).
The Centers of Medicare and Medicaid Services' transmittal describing its experiment that would alter ASP payment based on ZIP code, and a letter from oncology groups opposing the experiment (The Cancer Letter, March 4, 2016).
Fact sheet and other documents about Patrick Soon-Shiong's Cancer MoonShot 2020 Program (The Cancer Letter, Jan. 15, 2016).
2015 - Volume 41
Rep. Mike Fitzpatrick's letter to the FDA Office of Criminal Investigations, requesting an investigation on possible failures to report adverse outcomes resulting from power morcellators (The Cancer Letter, Dec. 18, 2015).
The slides presented by NCI Acting Director Douglas Lowy in his first director's report to the joint meeting of the NCAB and BSA (The Cancer Letter, July 3, 2015).
The letter sent to Amgen from attorneys representing The Cancer Letter (The Cancer Letter, June 5, 2015).
The protocol for the Duke breast cancer trial that treated Joyce Shoffner, and her complaint against Duke (The Cancer Letter, May 22, 2015).
The white paper produced by MED-C (The Cancer Letter, May 8, 2015).
MD Anderson officials respond to questions from The Cancer Letter (April 17, 2015).
An interview with Anil Potti (The Cancer Letter, Jan. 9, 2015).
2014 - Volume 40
A May 2014 version of a patient consent form for a Brigham & Women's Hospital study to assess leakage when using containment bags with power morcellators (The Cancer Letter, Nov. 21, 2014).
The statements and letters from Senators to FDA on power morcellation (The Cancer Letter, Nov. 21, 2014).
The data tables of NCI and NIH funding for 17 institutions from 2003 to 2013 (The Cancer Letter, Oct. 31, 2014).
The complaint filed by Pharmaceutical Research and Manufacturers of America against HHS and HRSA (The Cancer Letter, Oct. 24, 2014).
The review committee's report recommending the closing of the Indiana University Health Proton Therapy Center (The Cancer Letter, Oct. 17, 2014).
The Pharmaceutical Research and Manufacturers of America's (PhRMA) lawsuit against the Department of Health & Human Services/Health Resources and Services Administration for its 340B "interpretive" rule on the Affordable Care Act orphan drug exclusion (The Cancer Letter, Oct. 10, 2014).
The legal files regarding the DOJ prosecutions of those involved with the supply chain moving counterfeit Avastin into the United States (The Cancer Letter, Oct. 3, 2014).
The April 2006 letter sent from William McGivney to Genentech CEO Art Levinson (The Cancer Letter, Oct. 3, 2014).
The full confidential document detailing a plan for MD Anderson's nationwide expansion (The Cancer Letter, Sept. 26, 2014).
The back-and-forth correspondence between MD Anderson and the American Association of University Professors (The Cancer Letter, Sept. 19, 2014).
The letter from Sens. Chuck Schumer and Kirsten Gillibrand to FDA Commissioner Margaret Hamburg regarding power morcellation (The Cancer Letter, Aug. 27, 2014).
AAGL spokesperson Jubilee Brown's presentation slides and remarks July 11 to the FDA Obstetrics and Gynecology Devices Panel on power morcellation (The Cancer Letter, July 25, 2014).
Douglas Boyd's supporting documents sent to AAUP, making the case for an investigation into MD Anderson's decision to deny tenure to two faculty members (The Cancer Letter, May 16, 2014).
The complaint filed against Northwestern University, the plea agreement made by Feyifunmi Sangoleye, and the settlement agreement made between Northwestern and the Department of Justice (The Cancer Letter, Aug. 9, 2013).
MD Anderson President Ronald DePinho's Town Hall Meeting - January 2013 (The Cancer Letter, Jan. 18, 2013).
A recorded interview with Carolinas Healthcare System's Derek Raghavan. (The Cancer Letter, Jan. 4, 2013).
2012 Volume 38
William Gimson's resignation letter, from the Cancer Prevention & Research Institute of Texas (The Cancer Letter, Dec. 14, 2012).
Confirmation of an inquiry by the Texas Office of the Attorney General into CPRIT's funding of Peloton Therapeutics (The Cancer Letter, Dec. 14, 2012).
The letter from CPRIT's founding legislators expressing concern to CPRIT's investigators (The Cancer Letter, Dec. 14, 2012).
The letter from the Travis County District Attorney to Kristen Doyle, CPRIT's general counsel (The Cancer Letter, Dec. 14, 2012).
CPRIT's announcement of the appointment of Margaret Kripke as chief scientific officer (The Cancer Letter, Dec. 14, 2012).
An audio recording of Kripke's telephone conference with reporters (The Cancer Letter, Dec. 14, 2012).
A letter from Richard Schilsky to his colleagues at the University of Chicago.
The American Society of Clinical Oncology's press release announcing Richard Schilsky being named chief medical officer.
University of Chicago's notice to faculty announcing Richard Schilsky being named chief medical officer of the American Society for Clinical Oncology.
MD Anderson's August 2012 Financials (The Cancer Letter, Oct. 12, 2012).
The CPRIT Email Archive obtained by The Cancer Letter detailing the agency's reaction to MD Anderson's incubator proposal (The Cancer Letter, Sept. 28, 2012).
UT System documents pertaining to the hiring of DePinho and Chin (The Cancer Letter, Sept. 21, 2012).
The Opposition to Seal, sent by attorneys representing Amelia Weber (The Cancer Letter, April 20, 2012).
Urorad Healthcare's FAQ sheet regarding developing IMRT centers (The Cancer Letter, April 13, 2012).
TwinCrest Group's flyer to urology practices offering in-office pathology (The Cancer Letter, April 13, 2012).
Part one of a collection of files containing Craig Thompson's Motion to Dismiss, filed as part of the Abramson lawsuit (The Cancer Letter, March 23, 2012).
Part two of a collection of files containing Thompson's Motion to Dismiss (The Cancer Letter, March 23, 2012).
Agios Pharmaceuticals' Motion to Dismiss, filed against Abramson lawsuit (The Cancer Letter, March 23, 2012).
UPenn's complaint against former cancer center director, Craig Thompson (The Cancer Letter, March 9, 2012).
Attachments to UPenn's complaint (The Cancer Letter, March 9, 2012).
The Abramson Institute's complaint against former cancer center director, Craig Thompson (The Cancer Letter, March 9, 2012).
Duke University's letter to the president of the North Carolina Medical Board (The Cancer Letter, Dec. 9, 2011).
NC Medical Board Reprimands Former Duke Doctor Anil Potti. The text of the consent decree.
The email sent by Jerome Yates, former American Cancer Society VP for research, regarding the society's restructuring (The Cancer Letter, Nov. 18, 2011).
The TREAT Act, a model bill proposing two new options for FDA approval (The Cancer Letter, Nov. 18, 2011).
NCI CTEP's RFA Presentation to the Board of Scientific Advisors (The Cancer Letter, Nov. 11, 2011).
Exhibit E: Spreadsheets showing the overfill of Aranesp compared to Procrit, in US & Westmoreland vs. Amgen (The Cancer Letter, Oct. 28, 2011).
The whistle-blower lawsuit of US & Westmoreland vs. Amgen Inc. (The Cancer Letter, Oct. 28, 2011).
The US Preventive Services Task Force Systematic Review Of Evidence Draft Paper, via Annals of Internal Medicine (The Cancer Letter, Oct. 7, 2011).
The jointly filed lawsuit against Duke University, Duke University Health System, Potti, Nevins, et al. (The Cancer Letter, Sept. 9, 2011).
The filed lawsuit of Joyce Shoffner vs. Duke University, et al. (The Cancer Letter, Sept. 9, 2011).
Citizen Oncology Foundation's analysis of the drug shortage (The Cancer Letter, Sept. 9, 2011).
FDA CDER's Post-Hearing Submission against Avastin's MBC Indication (The Cancer Letter, Aug. 12, 2011).
Genentech's Post-Hearing Submission in favor of Avastin's MBC Indication (The Cancer Letter, Aug. 12, 2011).
The letter to Varmus and Doroshow from advocates for the Children's Oncology Group (The Cancer Letter, July 8, 2011).
The letter to Varmus and Doroshow from patients involved in the adult cancer cooperative groups (The Cancer Letter, July 8, 2011).
Aug. 5, 2005 issue of The Cancer Letter (The Cancer Letter, July 1, 2011).
Claudia Henschke's affadavit used in class action suits against Philip Morris USA (The Cancer Letter, June 24, 2011).
The 2009 tax filing by Henschke's Early Diagnosis and Treatment Research Foundation, Inc (The Cancer Letter, June 24, 2011).
The caBIG Program Update presented to the Board of Scientific Advisors (The Cancer Letter, June 24, 2011).
Internal NCI documents (zip files 1, 2 and 3) related to the Duke genomics controversy (The Cancer Letter, Jan. 7, 2011).
2010 Volume 36
NIH response to Sen. Charles Grassley on sponsored travel by NCI scientists (The Cancer Letter, Dec. 3, 2010).
NCI-funded CISNET model presented by Harvard researchers predicting outcome of National Lung Screening Trial (The Cancer Letter, Nov. 26, 2010).
Sen. Charles Grassley letter to NIH Director Francis Collins and NCI Director Harold Varmus on "sponsored travel" by NCI scientists (The Cancer Letter, Oct. 29, 2010.)
NCI letter of Oct. 15, 2010 on carboplatin dosing, referenced in The Cancer Letter, Oct. 22, 2010.
NCI Letter of Oct. 1, 2010, "Action Letter for Protocols Sponsored by the National Cancer Institute That Use Carboplatin." Referenced in The Cancer Letter, Oct. 8, 2010.
Documents on Avastin referenced in Sept. 3, 2010, issue of The Cancer Letter: Howard Burris letter; AdvancedBC.org letter; advocacy groups' letter to FDA; Kathy Miller letter to ES103 investigators; Gabriel Hortobagyi email; National Breast Cancer Coalition letter to FDA.
The Potti Scandal documents mentioned in The Cancer Letter, July 30, 2010: Potti's bio submitted to Department of Defense.
The Potti Scandal documents mentioned in The Cancer Letter, July 23, 2010: Letter by 33 biostatisticians to NCI Director Harold Varmus. Letter by American Cancer Society Chief Medical Officer Otis Brawley to Duke University. A list of Potti's technologies available for licensing from Duke. More detailed description of one of these technologies.
Duke scientist Anil Potti's different CVs: version 1, version 2, and version 3. His University of North Dakota Residency application, and a page from a Duke brochure listing his claimed Rhodes scholarship. The Cancer Letter, July 16, 2010.
City of Hope dispute with for-profit physician group reading materials (.zip file), referenced in The Cancer Letter, May 28, 2010.
Entertainment Industry Foundation's 2008 IRS Form 900, referenced in The Cancer Letter, May 21, 2010.
Documents on Duke University genomics research: Duke report and email obtained by The Cancer Letter; comments by biostatisticians on the report (The Cancer Letter, May 14, 2010).